Asad Haider
Stock Analyst at Goldman Sachs
(2.82)
# 1,630
Out of 5,245 analysts
15
Total ratings
71.43%
Success rate
19.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $92.14 | +54.11% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $234.34 | +2.42% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $35.44 | +4.40% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $59.46 | -4.14% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $22.46 | -24.31% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $54.50 | -22.94% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $47.30 | -19.66% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,065.00 | -16.62% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $215.70 | -10.06% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.90 | -3.47% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $92.14
Upside: +54.11%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $234.34
Upside: +2.42%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $35.44
Upside: +4.40%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $59.46
Upside: -4.14%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $22.46
Upside: -24.31%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $54.50
Upside: -22.94%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $47.30
Upside: -19.66%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,065.00
Upside: -16.62%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $215.70
Upside: -10.06%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.90
Upside: -3.47%